DOI QR코드

DOI QR Code

Effects of the Cyclin D1 Polymorphism on Lung Cancer Risk - a Meta-analysis

  • Li, Yue (Department of Medical Oncology, the Third Affiliated Hospital of Harbin Medical University) ;
  • Zhang, Shuai (Department of Medical Oncology, the Third Affiliated Hospital of Harbin Medical University) ;
  • Geng, Jian-Xiong (Department of Medical Oncology, the Third Affiliated Hospital of Harbin Medical University) ;
  • Yu, Yan (Department of Medical Oncology, the Third Affiliated Hospital of Harbin Medical University)
  • 발행 : 2012.05.30

초록

Background: Cyclin D1 (CCND1) is critical in the transition of the cell cycle from G1 to S phases and unbalanced cell cycle regulation is a hallmark of carcinogenesis. A number of studies conducted to assess the association between CCND1 G870A polymorphism and susceptibility to lung cancer have yielded inconsistent and inconclusive results. In the present study, the possible association above was assessed by a meta-analysis. Methods: Eligible articles were identified for the period up to November 2011. Pooled odds ratios (OR) with 95% confidence intervals (95%CI) were appropriately derived from fixed effects or random-effects models. Sensitivity analysis excluding studies whose genotype frequencies in controls significantly deviated from the Hardy-Weinberg equilibrium (HWE) was performed. Results: Ten case-control studies with a total of 10,548 subjects were eligible. At the overall analysis the CCND1 870A allele appeared to be associated with elevated lung cancer risk (for allele model, pooled OR = 1.24, 95% CI: 1.08-1.44, P = 0.004; for homozygous model, pooled OR = 1.45, 95% CI: 1.14-1.84, P = 0.003; for recessive model, pooled OR = 1.29, 95% CI: 1.06-1.58, P = 0.013; for dominant model, pooled OR = 1.33, 95% CI: 1.08-1.65, P = 0.009). Subgroup analyses by ethnicity and sensitivity analysis further pointed to associations, particularly in Asians. Conclusion: This meta-analysis suggests that the A allele of CCND1 G870A polymorphism confers additional lung cancer risk.

키워드

참고문헌

  1. Betticher DC, Heighway J, Hasleton PS, et al (1996). Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer, 73, 294-300. https://doi.org/10.1038/bjc.1996.52
  2. Brennan P, Hainaut P, Boffetta P (2011). Genetics of lung-cancer susceptibility. Lancet Oncol, 12, 399-408. https://doi.org/10.1016/S1470-2045(10)70126-1
  3. Buch S, Zhu B, Davis AG, et al (2005). Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog, 42, 222-8. https://doi.org/10.1002/mc.20086
  4. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  5. Egger M, Smith GD, Phillips AN (1997). Meta-analysis: principles and procedures. BMJ, 315, 1533-7. https://doi.org/10.1136/bmj.315.7121.1533
  6. Gautschi O, Hugli B, Ziegler A, et al (2006). Cyclin D1 (CCND1) A870G gene polymorphism modulates smokinginduced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer, 51, 303-11. https://doi.org/10.1016/j.lungcan.2005.10.025
  7. Herbst RS, Heymach JV, Lippman SM (2008). Lung cancer. N Engl J Med, 359, 1367-80. https://doi.org/10.1056/NEJMra0802714
  8. Higgins J, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Statistics in medicine, 21, 1539-58. https://doi.org/10.1002/sim.1186
  9. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  10. Hinds PW, Dowdy SF, Eaton EN, et al (1994). Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA, 91, 709-13. https://doi.org/10.1073/pnas.91.2.709
  11. Hsia TC, Liu CJ, Lin CH, et al (2011). Interaction of CCND1 genotype and smoking habit in Taiwan lung cancer patients. Anticancer Res, 31, 3601-5.
  12. Hung RJ, Boffetta P, Canzian F, et al (2006). Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. Cancer Res, 66, 8280-6. https://doi.org/10.1158/0008-5472.CAN-05-3099
  13. Knudsen KE, Diehl JA, Haiman CA, et al (2006). Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene, 25, 1620-8. https://doi.org/10.1038/sj.onc.1209371
  14. Li QP, Deng YJ, Xiao CJ, et al (2009). Comparative study of polymorphism of cyclinDl gene in patients with non small celI lung cancer from Xuanwei and Kunming. Shandong Yi Yao, 49, 1-3.
  15. Lu F, Gladden AB, Diehl JA (2003). An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res, 63, 7056-61.
  16. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  17. Musgrove EA, Caldon CE, Barraclough J, et al (2011). Cyclin D as a therapeutic target in cancer. Nat Rev Cancer, 11, 558-72. https://doi.org/10.1038/nrc3090
  18. Qiuling S, Yuxin Z, Suhua Z, et al (2003). Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis, 24, 1499-503. https://doi.org/10.1093/carcin/bgg035
  19. Salim EI, Jazieh AR, Moore MA (2011). Lung cancer incidence in the Arab league countries: risk factors and control. Asian Pac J Cancer Prev, 12, 17-34.
  20. Sobti RC, Kaur P, Kaur S, et al (2006). Effects of cyclin D1 (CCND1) polymorphism on susceptibility to lung cancer in a North Indian population. Cancer Genet Cytogenet, 170, 108-14. https://doi.org/10.1016/j.cancergencyto.2006.05.017
  21. Solomon DA, Wang Y, Fox SR, et al (2003). Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem, 278, 30339-47. https://doi.org/10.1074/jbc.M303969200
  22. Wang Q, Jiang YX, Li GF, et al (2008). The relationship between the Cyclin D1 (CCNDI) A870G gene polymorphism and nonsmall cell lung cancer in Yunnan. Med PhiIosophy, 29, 36-8.
  23. Wang R, Zhang JH, Li Y, et al (2003). The association of cyclin D1 (A870G) polymorphism with susceptibility to esophageal and cardiac cancer in north Chinese population (in Chinese). Tumor, 23, 364-6.
  24. Wang W, Spitz MR, Yang H, et al (2007). Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res, 13, 5974-81. https://doi.org/10.1158/1078-0432.CCR-07-0113
  25. Xiao H, Ding J, Gao S, et al (2011). Never smokers with lung cancer: analysis of genetic variants. Asian Pac J Cancer Prev, 12, 2807-9.

피인용 문헌

  1. Association of Cyclin D1 Variants with Head and Neck Cancer Susceptibility: Evidence from a Meta-analysis vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5645
  2. The CCND1 G870A Gene Polymorphism and Leukemia or Non-Hodgkin Lymphoma Risk: a Meta-analysis vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6923
  3. A Cyclin D1 (CCND1) Gene Polymorphism Contributes to Susceptibility to Papillary Thyroid Cancer in the Turkish Population vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7181